ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2751

Recurrent Pericarditis In Children and Adolescents: Etiology, Presentation, Therapies, and Outcomes In a Multicenter Retrospective Cohort Of 100 Patients

Antonio Brucato1, Massimo Imazio2, Marco Gattorno3, Antonella Insalaco4, Chiara Di Blasi Lo Cuccio1, Simona Marcora5, Rolando Cimaz6, Luca Cantarini7, Luciana Breda8, Manuela Marsili9, Fabrizia Corona10 and Alberto Martini11, 1Internal Medicine, USC Internal Medicine, Ospedale Papa Giovanni XXIII, Bergamo, Italy, 2Cardiology, Maria Vittoria Hospital, Torino, Italy, 3Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, 4Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, 5Paediatric Cardiology, Ospedale Papa Giovanni XXIII, Bergamo, Italy, 6Rheumatology Unit, A. Meyer Children's Hospital, Florence, Italy, 7University of Siena, Siena, Italy, 8Department of Paediatrics, University of Chieti G. D'Annunzio, Chieti, Italy, 9Paediatrics Department, University of Chieti G. D'Annunzio, Chieti, Italy, 10Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, 11Pediatria, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease and pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Autoinflammatory Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Acute pericarditis is defined as at least 2 of the following criteria: typical chest pain (sharp and pleuritic, improved by sitting up and leaning forward), pericardial friction rub, suggestive EKG changes (widespread ST elevation or PR depression), new or worsening pericardial effusion. Pericarditis may recur in 15-30% of cases, and these children are frequently followed by pediatric Rheumatologists. In up to 68% of pediatric patients and in more than 80% of adult cases a specific etiology cannot be detected and pericarditis is considered idiopathic. Suggested explanations of recurrences include: insufficient dose and/or duration of non-steroidal anti-inflammatory drugs (NSAIDs), early corticosteroid treatment causing increased viral replication in pericardial tissue, too rapid tapering of corticosteroids, re-infection and exacerbation of the connective tissue disease.

Methods: Multicenter, retrospective cohort study including all consecutive cases of recurrent pericarditis of patients aged <18 years with at least 2 recurrences of pericarditis seen in referral centers in Italy. The study included 100 cases of recurrent pericarditis (median 13 years, range 1-17 years, 62 males).  

Results: Pericarditis was idiopathic or viral in 87.0% of cases, post-pericardiotomy in 9.0% of cases; Familial Mediterranean Fever was diagnosed in 2.0% of cases, and a systemic inflammatory disease in 2.0% of cases. The majority of children had fever and CRP elevation at disease onset (96% fever, 98% CRP elevation), and pericardial effusion (57%), while pericardial rub (25%) and EKG changes (42%) were detected in a smaller percentage of patients. Corticosteroid-treated patients experienced more recurrences, side effects, and disease-related hospitalization (for all p<0.05). After a median follow up of 60 months (6-360 months), 470 recurrences were recorded (median 3, range 2-25). Duration of the active disease was unpredictable in the single patient and largely variable. Overall, 97% of cases had additional recurrences. ANA testing is ongoing. Additional adverse events during follow-up included: readmission in 74% of cases and cardiac tamponade in 13% of cases (in the first attacks). None of our patients diagnosed as having an idiopathic recurrent pericarditis developed a systemic autoimmune disease; 78% children were treated with NSAIDs, 62% with steroids and in 62% cases colchicine was added. Refractory cases (17%) were treated with immunosuppressant drugs (azathioprine, methotrexate, IVIG, Plaquenil), and 7 (7%) with Anakinra.  Long term outcome was good, with no evolution in constrictive pericarditis, cardiomyopathy or systemic rheumatic diseases.

Conclusion: this is the largest ever published case-series of pediatric recurrent pericarditis. NSAIDs and colchicines remain the mainstay of the therapy while corticosteroids should be used with extreme caution, particularly in pediatric patients. In cortico-dependent cases anti-IL1 drugs proved to be very effective. The long term outcome is good.


Disclosure:

A. Brucato,
None;

M. Imazio,
None;

M. Gattorno,
None;

A. Insalaco,
None;

C. Di Blasi Lo Cuccio,
None;

S. Marcora,
None;

R. Cimaz,
None;

L. Cantarini,
None;

L. Breda,
None;

M. Marsili,
None;

F. Corona,
None;

A. Martini,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/recurrent-pericarditis-in-children-and-adolescents-etiology-presentation-therapies-and-outcomes-in-a-multicenter-retrospective-cohort-of-100-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology